



OPEN ACCESS

# The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings

Joan Riera,<sup>1,2</sup> Simon Hyttel-Sorensen,<sup>3</sup> María Carmen Bravo,<sup>1</sup> Fernando Cabañas,<sup>4</sup> Paloma López-Ortego,<sup>1</sup> Laura Sanchez,<sup>1</sup> Marta Ybarra,<sup>1</sup> Eugene Dempsey,<sup>5</sup> Gorm Greisen,<sup>3</sup> Topun Austin,<sup>6</sup> Olivier Claris,<sup>7</sup> Monica Fumagalli,<sup>8</sup> Christian Gluud,<sup>9</sup> Petra Lemmers,<sup>10</sup> Gerhard Pichler,<sup>11</sup> Anne Mette Plomgaard,<sup>1</sup> Frank van Bel,<sup>10</sup> Martin Wolf,<sup>12</sup> Adelina Pellicer<sup>1</sup>

For numbered affiliations see end of article.

## Correspondence to

Joan Riera, Biomedical Engineer, Department of Neonatology, La Paz University Hospital, Paseo de la Castellana 261, Madrid ES-28046, Spain; joan.riera@me.com

Received 19 April 2015

Revised 7 October 2015

Accepted 13 October 2015

Published Online First

8 December 2015

## ABSTRACT

**Background** The SafeBoosC phase II randomised clinical trial recently demonstrated the benefits of a combination of cerebral regional tissue oxygen saturation (rStO<sub>2</sub>) by near-infrared spectroscopy (NIRS) and a treatment guideline to reduce the oxygen imbalance in extremely preterm infants.

**Aims** To analyse rStO<sub>2</sub>-alarm-related clinical decisions and their heterogeneity in the NIRS experimental group (NIRS monitoring visible) and their impact on rStO<sub>2</sub> and SpO<sub>2</sub>.

**Methods** Continuous data from NIRS devices and the alarms (area under the curve of the rStO<sub>2</sub> out of range had accumulated 0.2%/h during 10 min), clinical data at discrete time points and interventions prompted by the alarms were recorded.

**Results** Sixty-seven infants had data that fulfilled the requirements for this analysis. 1107 alarm episodes were analysed. The alarm triggered a treatment guideline intervention in 25% of the cases; the type of intervention chosen varied among clinical sites. More than 55% of alarms were not followed by an intervention ('No action'); additionally, in 5% of alarms the rStO<sub>2</sub> value apparently was considered non-reliable and the sensor was repositioned. The percentage of unresolved alarms at 30 min after 'No action' almost doubled the treatment guideline intervention (p<0.001). Changes in peripheral oxygen saturation (SpO<sub>2</sub>), were observed only after treatment guideline interventions.

**Conclusions** This study shows that 25% of rStO<sub>2</sub> alarms were followed by a clinical intervention determined by the treatment guideline. However, the rStO<sub>2</sub> and SpO<sub>2</sub> returned to normal ranges after the intervention, supporting the notion that decisions taken by the clinicians were appropriate.

**Trial registration number** ClinicalTrials.gov NCT01590316.

## INTRODUCTION

The SafeBoosC phase II randomised clinical trial was a pragmatic medical device trial to obtain evidence-based knowledge on the benefits and harms of cerebral monitoring using near-infrared spectroscopy (NIRS) as a part of routine management of premature infants.<sup>1</sup> NIRS-derived absolute regional cerebral tissue oxygen saturation (rStO<sub>2</sub>) is a composite measure of tissue oxygen saturation across arterial, capillary and venous beds and reflects a balance between cerebral oxygen delivery and consumption.<sup>2–5</sup> The aim of the SafeBoosC

## What is already known on this topic

Cerebral hypoxia and hyperoxia of infants are associated with adverse outcomes. A variety of studies, mostly observational, have addressed the effect of different interventions on brain oxygenation using near-infrared spectroscopy (NIRS). The benefits of a combination of cerebral NIRS and a dedicated treatment guideline to reduce the amount of oxygen imbalance in the brain have been recently reported (The SafeBoosC randomised clinical trial).

## What this study adds

This study reports on the SafeBoosC trial-related clinical decisions and their impact on the infant's condition. In addition, this study reports about the heterogeneity among participating centres, possibly due to a variety of local clinical care policies with a focus on the optimal design for a large-scale confirmatory trial.

phase II randomised clinical trial was the stabilisation of cerebral oxygenation by the combined use of rStO<sub>2</sub> monitoring and an evidence-based treatment guideline<sup>6</sup> as a brain-oriented protection strategy with the goal of reducing fluctuations in oxygen delivery and consumption.<sup>7–9</sup>

The treatment guideline was developed focusing on interventions that could have an impact on arterial oxygen saturation (SpO<sub>2</sub>), haemoglobin concentration and cerebral blood flow, which are the main determinants of oxygen delivery to the brain. This treatment guideline suggested potential interventions to be considered by the physicians within the range of the policies currently in place in their units.<sup>6</sup>

The SafeBoosC phase II randomised clinical trial demonstrated that cerebral oxygenation can be stabilised in extremely preterm infants during the first 3 days after birth with a median 58% reduction in the burden of hypoxia and hyperoxia in the experimental group in comparison with the control group.<sup>1</sup> The purpose of this report is to analyse the trial-related clinical decisions and their impact on



Open Access  
Scan to access more  
free content



CrossMark

**To cite:** Riera J, Hyttel-Sorensen S, Bravo MC, et al. *Arch Dis Child Fetal Neonatal Ed* 2016;**101**: F333–F338.

the infants' condition (rStO<sub>2</sub> and SpO<sub>2</sub>) as well as potential heterogeneity among the participating centres with a focus on the optimal design for a large scale, multicentre trial with a patient-relevant outcome.

## METHODS

### Design and study population

The trial included infants from eight different European countries. It was approved by each hospital's local research ethics committee, and, where required (Austria, Denmark, France, and Switzerland), by the competent authority responsible for medical devices. Details regarding the trial protocol, clinical characteristics of infants and main outcomes have been reported elsewhere.<sup>1–10</sup> Recruitment was conducted between June 2012 and December 2013. Briefly, infants of gestational age up to 27 weeks and 6 days, with the possibility to start cerebral NIRS monitoring within 3 h after birth, who had written informed consent, were considered eligible for the trial. By means of a central web-based randomisation system infants were allocated to either the experimental group, with the cerebral NIRS monitoring visible, or the control group with the cerebral NIRS monitoring blinded.

### Software analysing procedure and study workflow

In the experimental group the alarm was activated when the area under the curve (AUC) of the rStO<sub>2</sub> out of normal range, defined as rStO<sub>2</sub> between 55% and 85%, had accumulated 0.2%/h during the past 10 min.<sup>1</sup> The units are expressed as %h because the AUC is calculated from time (x-axis) and rStO<sub>2</sub>% (y-axis).

Software was specifically developed to calculate the alarm. The software received data from the NIRS device and calculated the AUC and generated the alarm. The software also showed trends in rStO<sub>2</sub> and provided a recording system for interventions related to the treatment guideline as well as a dataset (physiological and biochemical variables and ventilator settings).

The data were manually entered into this software programme by the clinical staff.

A dedicated treatment guideline was available to the clinical staff listing possible interventions to normalise an out of range rStO<sub>2</sub>.<sup>6</sup> The interventions were focused on respiratory and circulatory support and are described in detail elsewhere.<sup>6</sup> The treatment guideline was in accordance with the current national clinical practices. If an alarm prompted a clinical intervention this was reported in the software from a drop down menu listing various interventions. If a different intervention to that listed in the treatment guidelines was implemented, it was documented as 'Other'. If after careful evaluation, the attending staff judged that there was no reason to believe that the infant was compromised, then the decision was 'No action'.<sup>6</sup>

A dataset was recorded every 6 h according to the protocol and included heart rate, peripheral oxygen saturation (SpO<sub>2</sub>), mean arterial blood pressure, mean airway pressure, inspired oxygen fraction, and pH, blood gases, lactate, base excess, haemoglobin and glycaemia if available. These data were also requested at the start of the alarm and 30 min later (first review); in case the alarm was not resolved (AUC still above 0.2%/h in the last 10 min) within the first 30 min a second review dataset was also requested 30 min after the first review. The bedside software programme displayed the quality of the NIRS values provided by the device; this prevented missing values and false readings that could lead to inappropriate interventions. The various cerebral oximeters used in the study were comparable in terms of absolute value, repeatability and sensitivity to changes in oxygenation on the adult, human forearm.<sup>11–12</sup>

Local staff was trained as appropriate to supervise all participants during the intervention. To minimise skin irritation related to the device it was recommended to move the NIRS sensor to a different location at the skull as often as every 4 h to avoid damage from heat and/or pressure. Each NIRS sensor reposition was also documented.

### Data analysis

Each site downloaded data to the data management centre after completion of the participant's intervention period. Using a Matlab (MathWorks, Natick, Massachusetts, USA) script created for this purpose, NIRS files, event files (decisions and sensor reposition information) and dataset were preprocessed. Data were reviewed manually to check data consistency.

Sensor reposition that occurred within the 10 min period following a previous sensor site reposition was considered a single event. In addition, NIRS sensor repositioning occurring within the 10 min period that followed an alarm in which the decision taken was 'No action' was analysed separately; this was considered as an intervention that was termed 'Alarm-prompted reposition'. In these cases the alarm apparently was judged to be the consequence of poor sensor-skin contact yielding to non-reliable warning. Alarms occurring within the 15 min period following sensor repositioning were discarded.

### Statistics

The data were analysed using the statistical software SAS V.9.2 (Cary, North Carolina, USA). The quantitative data are given as means (SD or 95% CI) or median (IQR) and the qualitative data as counts and percentages. Mixed-model analysis was used to adjust the effect of repeated measures per centre or total population. To avoid the effect of variations in study duration among infants results are expressed as 'per time unit'.

In addition to rStO<sub>2</sub>, the peripheral SpO<sub>2</sub> was chosen as the physiological variable to evaluate the impact of warnings and

**Table 1** Perinatal and neonatal data of the study population

Gestational age (w), mean (SD)	26.38 (1.18)
Birth weight (g), mean (SD)	854 (206)
Male, n (%)	36 (54)
Multiple, n (%)	13 (19)
Apgar score ≤5 at 5 min, n (%)	11 (16)
Antenatal steroids, n (%)	49 (73)
Chorioamnionitis, n (%)	6 (9)
Rupture of membranes, >24 h before labour n (%)	21 (31)
Surfactant administered*, n (%)	52 (78)
Mechanical ventilation*, n (%)	46 (69)
Treatment for patent ductus arteriosus*, n (%)	13 (19)
Necrotising enterocolitis†, n (%)	9 (13)
Retinopathy of prematurity‡, n (%)	12 (18)
Severe brain injury§, n (%)	9 (14)
Periventricular haemorrhagic infarction	6 (9)
Grade 3 intraventricular haemorrhage	2 (3)
Posthaemorrhagic ventricular dilatation	3 (4.6)
Lenticuloatrial stroke	1 (1.5)
Death before discharge, n (%)	7 (10)

\*Refers to the intervention period (first 72 h from birth).

†Modified Bell's stage 2 or 3.<sup>13</sup>

‡Stage 3 or worse on international classification.<sup>14</sup>

§Overall cranial ultrasound score reflecting the worst of the serial scans from birth to discharge or death.

**Table 2** Decision taken by clinicians in response to alarm per centre

Centre	Alarm/h per patient (95% CI)	Treatment guideline intervention				Alarm-prompted reposition, n (%)
		Total n (%)	FiO <sub>2</sub> adjustment n (%)*	No action, n (%)	Other, n (%)	
1	0.32 (0.07 to 0.55)	38 (24)	35 (92)	100 (63)	16 (10)	5 (3)
2	0.39 (0.22 to 0.56)	78 (22)	65 (83)	196 (56)	66 (19)	13 (4)
3	0.09 (0.06 to 0.11)	30 (26)	9 (30)	33 (29)	26 (23)	26 (23)
4	0.16 (0.06 to 0.27)	31 (42)	27 (87)	38 (52)	4 (5)	0 (0)
5	0.19 (0.12 to 0.28)	40 (22)	15 (37)	115 (65)	20 (11)	3 (2)
6	0.33 (0.02 to 0.58)	18 (19)	16 (89)	57 (61)	16 (17)	2 (2)
7	0.24 (0.01 to 0.46)	37 (37)	32 (86)	49 (49)	9 (9)	4 (4)
8	0.32 (0.12 to 0.90)	4 (11)	2 (50)	27 (73)	2 (5)	4 (11)
Total	0.23 (0.18 to 0.29)	276 (25)	201 (73)	615 (56)	159 (14)	57 (5)

\*FiO<sub>2</sub> adjustment expressed as percentage within the treatment guideline interventions.

eventual clinical decisions on the infants' status. The peripheral SpO<sub>2</sub> value was calculated as the averaged mean value entered at the time of the alarm and at 30 and 60 min of warning. The rStO<sub>2</sub> value was derived from the averaged mean of all samples obtained during 1 min at the time datasets were entered. The unresolved alarm by time according to type of decision taken by clinicians was represented using the Kaplan and Meier method; differences were assessed by means of the log-rank test.

## RESULTS

Among the 86 infants included in the SafeBoosC trial in the NIRS experimental group,<sup>1</sup> 67 (78%) had data that fulfilled the requirements for this analysis. The remaining 19 infants were excluded due to inappropriate use of the study software. Infants were recruited in eight different centres, with a variable number of infants in the experimental group per centre (ranging from 2 to 18). The mean duration of NIRS recordings during the intervention period was 70.24 (SD 9.22) hours without differences between centres. The clinical characteristics of the study population are detailed in table 1.

Periodical repositioning per protocol of the NIRS sensor, as suggested in the protocol, varied according to centre ( $p < 0.001$ ), with a median of 0.18 (IQR 0.19) repositions


per hour (ranges 0.0–0.28). No differences in sensor reposition according to NIRS device were found.

A total of 1107 alarm episodes (cerebral hypoxia, 874; cerebral hyperoxia, 233) were analysed from the 67 infants. The decision taken in relation to alarm varied according to centre ( $p = 0.001$ ) (table 2). The alarm triggered a treatment guideline intervention in 25% of the total alarm episodes (figure 1). In most treatment guideline interventions the choice was a change in FiO<sub>2</sub>, consisting of an increase in FiO<sub>2</sub> in 177 (88.1%) episodes and a decrease in FiO<sub>2</sub> in 24 (11.9%) episodes.


Statistically significant differences were found among centres in relation to the type of intervention chosen ( $p = 0.001$ ). Centres 1, 2, 4, 6 and 7 were more prone to FiO<sub>2</sub> adjustment, whereas centres 3 and 5 chose more often a different balance between FiO<sub>2</sub> and ventilator settings. The time needed for the alarm to resolve varied according to type of decision taken ( $p < 0.001$ ) (figure 2).

We explored the impact of the decision taken on SpO<sub>2</sub>. The averaged mean SpO<sub>2</sub> at start of the alarm warning was 90.0% (SD 9.6), while it was 92.4% (SD 6.8) at the first (30 min) and 92.9% (SD 6.7) at the second (60 min) review. However, the profile of SpO<sub>2</sub> and rStO<sub>2</sub> changes showed differences according to the decisions taken in response to alarm (figure 3). Higher FiO<sub>2</sub> was associated with lower rStO<sub>2</sub> ( $p = 0.057$ ) and

**Figure 1** Flow diagram describing the potential decisions offered in response to an alarm and the distribution of choices according to the clinical staff preference. PDA, patent ductus arteriosus.



**Figure 2** Kaplan–Meier plot diagram representing the time needed for the alarm to be resolved according to type of decision taken (differences between ‘No action’ and ‘Treatment guideline intervention’ ( $p < 0.001$ ); ‘Alarm-prompted reposition’ ( $p = 0.001$ ); ‘Other’ ( $p = 0.009$ )). Unresolved alarms, percentage of alarms that remain active.



SpO<sub>2</sub> ( $p < 0.001$ ). Table 3 shows rStO<sub>2</sub> and SpO<sub>2</sub> according to the level of supplemental oxygen at the time of dataset.

## DISCUSSION


This report focuses on the alarm episodes analyses and the decisions taken in the experimental group (visible NIRS) of the SafeBoosC phase II randomised clinical trial. The alarm warned the clinical staff of situations where the brain could be exposed to hypoxia or hyperoxia, and potential clinical interventions were suggested in a treatment guideline<sup>6</sup> to normalise an out of range rStO<sub>2</sub>. However, more than 55% of the warning episodes were not followed by an intervention. Two important aspects need to be considered. First, the infants in the study were monitored by other devices apart from NIRS and only the interventions triggered by NIRS warnings were recorded in the SafeBoosC phase II trial software. Second, the NIRS alarm accumulated the values of rStO<sub>2</sub> obtained over the preceding 10 min, while the other monitoring systems did not (real-time reading and immediate alert system). These facts raise two important limitations of the present study. On the one hand, if compromised cerebral perfusion–oxygenation was suspected, successful treatment interventions may have been driven by other monitoring devices, such as transcutaneous blood gas monitoring, pulse oximetry or others, and been implemented before the NIRS alarm warned the clinicians (not enough time to accumulate an out of range rStO<sub>2</sub>). On the other hand, if the intervention triggered by other devices was not rapidly effective and the infant’s impaired condition was maintained for a longer period, the accumulated out of range rStO<sub>2</sub> would have triggered an alarm; in this case, the clinician eventually might have decided not to take any further action because appropriate action had already been implemented some minutes earlier. This may falsely inflate the ‘No action’ response. As there is no alternative monitoring system for the continuous assessment of brain oxygenation the possibility to address these issues is limited. We would like to remark that evidence supporting the treatment guideline interventions is relatively low and cannot be recommended outside a research setting.

The time needed for the alarm to be resolved varied according to the type of the decision taken (figure 2). Sensor repositioning (‘Alarm-prompted reposition’) returned rStO<sub>2</sub> to normal values (55%–85%) within 30min in 80% of alarms and within

100 min in all alarms. The percentage of alarms not resolved at 30 and 60 min after ‘No action’ were almost double compared with those in which there was an intervention (‘Treatment guideline intervention’). Yet, despite an intervention, 15% of these were unresolved by 60 min. This means that even if the intervention chosen was appropriate, the mechanism involved in improving brain perfusion–oxygenation takes more time to be fully resolved. Finally, in some very ill infants, it is likely that cerebral hypoxia has been resistant to all interventions. It is important to note, however, that data collection may have varied both within and between centres. As it was manually entered, some interventions may not have been properly documented. Furthermore, the 30 and 60 min points are likely to be insufficient to catch the details of multiple interventions. In the design of the study we chose those to avoid overloading the clinical staff with registration and thereby compromising the primary purpose of the trial.

To further evaluate the impact of alarms and decisions we analysed the evolution of SpO<sub>2</sub> and rStO<sub>2</sub> at the time of the alarm and the subsequent reviews according to the type of decision taken by the clinician. As illustrated in figure 3, when the decision was a ‘Treatment guideline intervention’ the averaged mean SpO<sub>2</sub> showed the greatest change, from the lowest mean value at start of warning to a more physiological and stable post-warning average value at first (30 min) and second (60 min) reviews. Interestingly, when the decision was ‘No action’, the averaged mean SpO<sub>2</sub> did not significantly vary, and remained during the whole intervention period within ‘acceptable’ clinical ranges. More obviously, repositioning the NIRS sensor did not change SpO<sub>2</sub>. Thus, trends in SpO<sub>2</sub> support the contention that the decisions taken by clinicians were appropriate in most cases. As the average SpO<sub>2</sub> at the time of the rStO<sub>2</sub> alarm was as low as 85%, it is not a surprise that the most common intervention was to increase FiO<sub>2</sub>. It is more of a surprise that the FiO<sub>2</sub> was not increased before the rStO<sub>2</sub> alarm as most units target SpO<sub>2</sub> at 90%–95%.

We found a negative association between FiO<sub>2</sub> and both rStO<sub>2</sub> and SpO<sub>2</sub>. By stratifying the group into (a) infants in room air, (b) infants on low supplementary oxygen (22%–29%) and (c) infants on high oxygen supplementation (>29%), we found that the impact of FiO<sub>2</sub> on rStO<sub>2</sub> and SpO<sub>2</sub> differed. The healthier the infant was (and so, the lower the supplementary



**Figure 3** Impact of type of decision taken in response to alarm episodes on the rStO<sub>2</sub> and the peripheral oxygen saturation (SpO<sub>2</sub>) used as a physiological proxy of cerebral oxygen saturation (rStO<sub>2</sub>). The rStO<sub>2</sub> (hypoxia, (A); hyperoxia, (B)) and SpO<sub>2</sub> (C) averaged means (95% CI) at onset of the alarm and at first (30 min) and second (60 min) review are represented.

**Table 3** Cerebral (rStO<sub>2</sub>) and peripheral (SpO<sub>2</sub>) oxygen saturation according to level of inspired supplemental oxygen (FiO<sub>2</sub>)

FiO <sub>2</sub> value (%)	rStO <sub>2</sub> % (SD) (n)	SpO <sub>2</sub> % (SD) (n)
21	64.9 (15.9) (580)	94.5 (5.2) (711)*
22–29	67.3 (14.8) (376)†	92.8 (4.6) (447)
≥30	63.8 (11.8) (149)†	92.0 (4.1) (180)

\*Differences between 21% and the other two FiO<sub>2</sub> strata (p<0.001).

†Differences between 21% and 22%–29% FiO<sub>2</sub> strata (p=0.001).

oxygen needs) the higher the associated rStO<sub>2</sub> and SpO<sub>2</sub> values were (table 3). This also supports the notion that other treatment strategies suggested by the treatment guidelines, apart from FiO<sub>2</sub> adjustment, contributed to the return of rStO<sub>2</sub> to normal ranges, particularly in the sickest infants.

In our experience, the rStO<sub>2</sub> alarm defined in this study protocol was rarely used to initiate treatment of a patent ductus arteriosus or guiding glucose intake. The former is more dependent on the variations in neonatal intensive care unit policies with regards to early echocardiographic assessment in these infants.

We observed wide differences in sensor repositioning among the participating centres. This difference was not explained by the brand of NIRS device used but possibly by differences in sensor fixation, registration of repositioning or compliance with the standard operating procedure among centres.

On average four interventions for infants in the experimental group achieved the 58% reduction in the AUC of hyperoxia and hypoxia that we previously reported.<sup>1</sup> As previously stated our data collection was not perfect and an in-depth analysis of the complex interaction of cerebral NIRS and the already available monitoring systems is difficult. From the results presented here it seems that cerebral NIRS monitoring did add some information that resulted in additional interventions. This was expected. Treatment was not changed in 75% of alarms. This may seem high, but it would on the other hand be surprising if out of range NIRS always resulted in interventions in such complex clinical scenarios as presented by this study population. Whether the NIRS monitoring also hindered some interventions is uncertain. Finally, we observed heterogeneity in the number of alarms between centres. We speculate this could be due to differences in clinical staff training on NIRS monitoring among the study participants<sup>1</sup> and in the severity of infant conditions. The patient-relevant clinical benefit of this complex intervention remains to be determined.

The absolute values provided by cerebral NIRS have shown poor repeatability and differences between the varied devices.<sup>15 16</sup> To deal with this, systematic pretrial testing was conducted using several NIRS instruments.<sup>11 17</sup> Only two NIRS devices were used in this study reducing heterogeneity. We have to depend on the absolute values of cerebral tissue oxygenation and on absolute thresholds for intervention.

## CONCLUSIONS

This post hoc analysis of the alarm episodes and their subsequent management in the experimental group of the SafeBoosC II randomised clinical trial revealed that three quarters of all alarms triggered were not followed by an active intervention at the bedside, suggesting that the treating clinician was content with the infant's overall status despite a cerebral oxygen outside

of the monitoring range. However, 25% of the alarms triggered a treatment guideline intervention, averaging four interventions per infant, supporting the strength of this non-invasive monitoring system. Limitations of the study design, however, restrict the generalisability of the results. For a large-scale trial of monitoring of cerebral oxygenation with patient-relevant outcomes study staff must be adequately trained in the application of NIRS and the pathophysiological basis for the choice of intervention.

#### Author affiliations

<sup>1</sup>Department of Neonatology, La Paz University Hospital, Madrid, Spain

<sup>2</sup>Center for Biomedical Technology, Technical University, Madrid, Spain

<sup>3</sup>Department of Neonatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>4</sup>Biomedical Research Foundation, La Paz University Hospital-IdiPAZ, Madrid, Spain

<sup>5</sup>Department of Paediatrics and Child Health, University College Cork, Cork, Ireland

<sup>6</sup>Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

<sup>7</sup>Department of Neonatology, Hopital Femme Mere Enfants, Bron, France

<sup>8</sup>NICU, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>9</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>10</sup>University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands

<sup>11</sup>Department of Pediatrics, Medical University of Graz, Graz, Austria

<sup>12</sup>Biomedical Optics Research Laboratory, Division of Neonatology, University Hospital Zurich, Zurich, Switzerland

**Acknowledgements** All authors critically reviewed the revised versions of the paper and approved the final draft for submission. All the authors had access to the data and contributed substantially to the submitted report. There were no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.

**Contributors** JR, SH-S, AP, TA, FvB, OC, ED, MF, CG, PL, AMP, GP, MW and GG conceived and designed the study. JR designed the boxes for blinding the device displays and designed and maintained the NIRS data collection software. JR, SH-S, AP, TA, FvB, OC, ED, MF, CG, PL, GP, AMP, MCB, FC, PLO, LS, MY and GG assisted with acquisition of the data. JR, MCB, FC, PLO, LS, MY and AP analysed the data. JR and AP wrote the initial draft. All authors critically reviewed revised versions of the paper and approved the final draft for submission. All the authors had access to the data and contributed substantially to the submitted report. JR and AP are the guarantors.

**Funding** This work was supported by an unconditional and unrestricted grant from the Danish Council for Strategic Research (DKK 11 100 105) and the SAMID network (RD08/0072/0018 and RD12/0026/0004). The funder had no role in the design, conduct, or analysis of the trial.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** This study was approved by the local ethics committees: clinical research ethics committee of the Cork Teaching Hospitals (EMC 3 (03/07/12)); NRES Committee East of England—Cambridge South (12/EE/0329); Ethikkommission Medizinische Universität Graz (24-261 ex (11/12)); De Videnskabetiske Komiteer—Region Hovedstaden (H-4-2012-028); CPP Sud-Est III—Lyon (HCLUP 2012.728); Direzione Scientifica-Comitato di Etica—The IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico (549/12-all.3); Medisch Ethische Toetsingscommissie—Universitair Medisch Centrum Utrecht (WAG/rc/12/036774); and Comité Ético de

Investigación Clínica del Hospital Universitario "La Paz" de Madrid (15/2011). All participants gave informed consent before taking part in the trial.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Dataset and alarm values are available from the corresponding author on request. Consent was not obtained but the presented data are anonymised and risk of identification is low.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

#### REFERENCES

- Hyttel-Sørensen S, Pellicer A, Alderliesten T, *et al*. Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial. *BMJ* 2015;350:g7635.
- Pellicer A, Bravo Mdel C. Near-infrared spectroscopy: a methodology-focused review. *Sem Fetal Neonatal Med* 2011;16:42–9.
- Wolf M, Greisen G. Advances in near-infrared spectroscopy to study the brain of the preterm and term neonate. *Clin Perinatol* 2009;36:807–34, vi.
- Nagdyman N, Fleck T, Schubert S, *et al*. Comparison between cerebral tissue oxygenation index measured by near-infrared spectroscopy and venous jugular bulb saturation in children. *Intensive Care Med* 2005;31:846–50.
- Tyree K, Tyree M, DiGeronimo R. Correlation of brain tissue oxygen tension with cerebral near-infrared spectroscopy and mixed venous oxygen saturation during extracorporeal membrane oxygenation. *Perfusion* 2009;24:325–31.
- Pellicer A, Greisen G, Benders M, *et al*. The SafeBoosC Phase II Randomised Clinical Trial: A treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants. *Neonatology* 2013;104:171–8.
- Greisen G, Leung T, Wolf M. Has the time come to use near-infrared spectroscopy as a routine clinical tool in preterm infants undergoing intensive care? *Philos Transact A Math Phys Eng Sci* 2011;369:4440–51.
- van Bel F, Lemmers P, Naulaers G. Monitoring neonatal regional cerebral oxygen saturation in clinical practice: value and pitfalls. *Neonatology* 2008;94:237–44.
- Toet MC, Lemmers P. Brain monitoring in neonates. *Earl Hum Dev* 2009;85:77–84.
- Hyttel-Sørensen S, Austin T, van Bel F, *et al*. A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial. *Trials* 2013;14:120.
- Hyttel-Sørensen S, Sorensen LC, Riera J, *et al*. Tissue oximetry: a comparison of mean values of regional tissue saturation, reproducibility and dynamic range of four NIRS-instruments on the human forearm. *Biomed Opt Express* 2011;2:3047–57.
- Hyttel-Sørensen S, Hessel TW, Greisen G. Peripheral tissue oximetry: comparing three commercial near-infrared spectroscopy oximeters on the forearm. *J Clin Monit Comput* 2014;28:149–55.
- Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. *Pediatr Clin North Am* 1986;33:179–201.
- International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. *Arch Ophthalmol* 2005;123:991–9.
- Sorensen LC, Greisen G. Precision of measurement of cerebral tissue oxygenation index using near-infrared spectroscopy in preterm neonates. *J Biomed Opt* 2006;11:054005.
- Hessel TW, Hyttel-Sørensen S, Greisen G. Cerebral oxygenation after birth—a comparison of INVOS® and FORE-SIGHT™ near-infrared spectroscopy oximeters. *Acta Paediatr* 2014;103:488–93.
- Hyttel-Sørensen S, Kleiser S, Wolf M, *et al*. Calibration of a prototype NIRS oximeter against two commercial devices on a blood-lipid phantom. *Biomed Opt Express* 2013;4:1662–72.